Kiniksa Pharmaceuticals International PLC

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 940.11, 1133.79, 1279.77, 1425.03, 1579.73 ], "ebit_estimate": [ 145.7, 212.13, 266.68, 334.08, 508.88 ], "ebitda_estimate": [ 160.99, 242.97, 330.57, null, null ], "net_income_estimate": [ 108.41, 155.14, 207.94, 262.43, 403.48 ], "per_share_eps_estimate": [ 1.18, 2.15, 3.12, 4.22, 3.9 ], "eps_nri_estimate": [ 1.25, 1.75, 2.5, 2.88, 4.38 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 10.05, 13.37, null, null, null ], "pretax_income_estimate": [ 161.97, 227.5, 299.53, 371.53, 552.85 ], "operating_cash_flow_per_share_estimate": [ -1.37, 6.3, null, null, null ], "roa_estimate": [ 11.4, 14.9, null, null, null ], "roe_estimate": [ 19.31, 22.04, 27.99, null, null ], "gross_margin_estimate": [ 88.78, 88.68, 88.9, 88.57, 88.23 ], "operating_cash_flow_estimate": [ -112.9, 519.18, null, null, null ], "pettm_estimate": [ 53.9, 29.55, 20.37, 15.02, 16.27 ], "long_term_growth_rate_mean": 48.53, "long_term_revenue_growth_rate_mean": "23.30", "future_per_share_eps_estimate_growth": 62.79, "future_eps_nri_estimate_growth": 48.53, "future_revenue_estimate_growth": 23.3, "future_ebit_estimate_growth": 50.59, "future_ebitda_estimate_growth": 60.23, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 51.25, "future_pretax_income_estimate_growth": 48.96, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 31.54, "future_gross_margin_estimate_growth": 0.11, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 225.46, 240.84, 257.88, 271.35, 284.25, 295.45, 304 ], "ebit_estimate": [ 31.61, 37.73, 46.57, 37, 39, 39, 40 ], "ebitda_estimate": [ 30.34, 38.82, 61.07, null, null, null, null ], "net_income_estimate": [ 23.71, 27.05, 34.22, 26, 27, 27, 28 ], "per_share_eps_estimate": [ 0.27, 0.32, 0.32, 0.38, 0.4, 0.41, 0.45 ], "eps_nri_estimate": [ 0.3, 0.35, 0.38, 0.37, 0.39, 0.41, 0.44 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ 34.34, 39.5, 49.45, 37, 39, 39, 40 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ 89.1, 89, 87.97, 90, 90, 90, 89 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 49.45, 45.15, 42.29, 38.92, null, null, null ], "long_term_growth_rate_mean": 48.53, "long_term_revenue_growth_rate_mean": "23.30", "future_per_share_eps_estimate_growth": 62.79, "future_eps_nri_estimate_growth": 48.53, "future_revenue_estimate_growth": 23.3, "future_ebit_estimate_growth": 50.59, "future_ebitda_estimate_growth": 60.23, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 51.25, "future_pretax_income_estimate_growth": 48.96, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": 31.54, "future_gross_margin_estimate_growth": 0.11, "future_operating_cash_flow_per_share_estimate_growth": null }